Critical Care
Volume 13
Issue 3 |
Viewing options:Associated material:Related literature:- Articles citing this article
- Other articles by authors
- Related articles/pages
Tools:
Post to:
|
CommentaryNICE-SUGAR: the end of a sweet dream?Jean-Charles Preiser  Department of Intensive Care, Centre Hospitalier Universitaire du Sart Tilman, 4000 Liege, Belgium  author email corresponding author email
Critical Care 2009,
13:143doi:10.1186/cc7790 Abstract
The results of the NICE-SUGAR (Normoglycaemia in Intensive Care Evaluation Survival Using Glucose Algorithm Regulation) trial were released last March. The primary outcome variable, 90-day mortality, was actually increased in patients randomly assigned to intensive insulin therapy, as compared with an intermediate target range for blood glucose. These findings, reflecting data collected in a set of more than 6,000 patients, clearly refute the external validity of tight glucose control. Future research will probably focus on several questions raised by the divergent results reported from investigations in the field of glucose control in the critically ill. | 
on Google Scholar
